WRAL Tech Wire

DURHAM, N.C. – Shareholders of Talecris Biotherapeutics (Nasdaq: TLCR) voted to approve a merger with Grifols (GRF.MC) during a special meeting held Monday at the Research Triangle Park Marriott in Durham.

Shareholders holding more than 108 million shares of Talecris common stock, out of a total of 125 million, voted in favor of the merger, according to reports.

In a regulatory filing with the Securities and Exchange Commission, Grifols said it would give the U.S. Federal Trade Commission (FTC) 30 days notice on the date of closure for its Talecris bid, and that closure would not be before March 21.

Earlier this month Grifols extended the deadline to complete the deal to March 6.

Grifols, a Spanish holding company specializing in the pharmaceutical-hospital sector in more than 90 countries, launched its $4 billion bid for Talecris in June to become the world’s third largest maker of blood plasma products, competing with rivals such as Baxter International (BAX.N) and Australia’s CSL (CSL.AX).

Talecris, based in Research Triangle Park, is North Carolina’s largest biotechnology company that makes drugs from blood plasma such as Gamunex and Prolastin to treat auto-immune diseases and other ailments. The company also owns plasma-collection centers.

The FTC currently is reviewing the terms of the deal, and most Wall Street analysts predict it will win approval. The FTC blocked an earlier Talecris takeover by an Australian company because of antitrust concerns.

Last week, Grifols completed financing it needed for the takeover of Talecris.

Monday’s meeting had originally been scheduled for Jan. 21. Talecris shareholders as of Jan. 11 were able to vote.

Get the latest news alerts: Follow LTW at Twitter.